251 related articles for article (PubMed ID: 28134290)
21. Targeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells.
Lai IL; Chou CC; Lai PT; Fang CS; Shirley LA; Yan R; Mo X; Bloomston M; Kulp SK; Bekaii-Saab T; Chen CS
Carcinogenesis; 2014 Oct; 35(10):2203-13. PubMed ID: 24879635
[TBL] [Abstract][Full Text] [Related]
22. Histone deacetylase inhibitor augments anti-tumor effect of gemcitabine and pegylated interferon-α on pancreatic cancer cells.
Iwahashi S; Shimada M; Utsunomiya T; Morine Y; Imura S; Ikemoto T; Mori H; Hanaoka J; Sugimoto K; Saito Y
Int J Clin Oncol; 2011 Dec; 16(6):671-8. PubMed ID: 21556798
[TBL] [Abstract][Full Text] [Related]
23. Suppression of Tumor Growth and Muscle Wasting in a Transgenic Mouse Model of Pancreatic Cancer by the Novel Histone Deacetylase Inhibitor AR-42.
Henderson SE; Ding LY; Mo X; Bekaii-Saab T; Kulp SK; Chen CS; Huang PH
Neoplasia; 2016 Dec; 18(12):765-774. PubMed ID: 27889645
[TBL] [Abstract][Full Text] [Related]
24. Effects and mechanisms of the combination of suberoylanilide hydroxamic acid and bortezomib on the anticancer property of gemcitabine in pancreatic cancer.
Lee JK; Ryu JK; Yang KY; Woo SM; Park JK; Yoon WJ; Lee SH; Jeong KS; Kim YT; Yoon YB
Pancreas; 2011 Aug; 40(6):966-73. PubMed ID: 21487323
[TBL] [Abstract][Full Text] [Related]
25. A G-Quadruplex-Binding Small Molecule and the HDAC Inhibitor SAHA (Vorinostat) Act Synergistically in Gemcitabine-Sensitive and Resistant Pancreatic Cancer Cells.
Ahmed AA; Neidle S
Molecules; 2020 Nov; 25(22):. PubMed ID: 33227941
[TBL] [Abstract][Full Text] [Related]
26. Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors.
Haefner M; Bluethner T; Niederhagen M; Moebius C; Wittekind C; Mossner J; Caca K; Wiedmann M
World J Gastroenterol; 2008 Jun; 14(23):3681-92. PubMed ID: 18595135
[TBL] [Abstract][Full Text] [Related]
27. Renoprotective Effect of the Histone Deacetylase Inhibitor CG200745 in DOCA-Salt Hypertensive Rats.
Bae EH; Kim IJ; Song JH; Choi HS; Kim CS; Eom GH; Kim I; Cha H; Cho JM; Ma SK; Kim SW
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30691015
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of histone deacetylases protects septic mice from lung and splenic apoptosis.
Takebe M; Oishi H; Taguchi K; Aoki Y; Takashina M; Tomita K; Yokoo H; Takano Y; Yamazaki M; Hattori Y
J Surg Res; 2014 Apr; 187(2):559-70. PubMed ID: 24290430
[TBL] [Abstract][Full Text] [Related]
29. Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth.
Nagaraj NS; Washington MK; Merchant NB
Clin Cancer Res; 2011 Feb; 17(3):483-93. PubMed ID: 21266529
[TBL] [Abstract][Full Text] [Related]
30. Antitumor activity and combined inhibitory effect of ceritinib with gemcitabine in pancreatic cancer.
Jamshed MB; Munir F; Shahid N; Sadiq U; Muhammad SA; Ghanem NB; Zhong H; Li X; Zhang Q
Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G109-G119. PubMed ID: 31736340
[TBL] [Abstract][Full Text] [Related]
31. Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models.
Rabia E; Garambois V; Hubert J; Bruciamacchie M; Pirot N; Delpech H; Broyon M; Theillet C; Colombo PE; Vie N; Tosi D; Gongora C; Khellaf L; Jarlier M; Radosevic-Robin N; Chardès T; Pèlegrin A; Larbouret C
MAbs; 2021; 13(1):1914883. PubMed ID: 33876707
[TBL] [Abstract][Full Text] [Related]
32. Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model.
Brandes F; Schmidt K; Wagner C; Redekopf J; Schlitt HJ; Geissler EK; Lang SA
BMC Cancer; 2015 Feb; 15():71. PubMed ID: 25884642
[TBL] [Abstract][Full Text] [Related]
33. HNF1A inhibition induces the resistance of pancreatic cancer cells to gemcitabine by targeting ABCB1.
Lu Y; Xu D; Peng J; Luo Z; Chen C; Chen Y; Chen H; Zheng M; Yin P; Wang Z
EBioMedicine; 2019 Jun; 44():403-418. PubMed ID: 31103629
[TBL] [Abstract][Full Text] [Related]
34. BH3 Mimetic ABT-199 Enhances the Sensitivity of Gemcitabine in Pancreatic Cancer in vitro and in vivo.
Zhou Y; Liu H; Xue R; Tang W; Zhang S
Dig Dis Sci; 2018 Dec; 63(12):3367-3375. PubMed ID: 30155839
[TBL] [Abstract][Full Text] [Related]
35. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
[TBL] [Abstract][Full Text] [Related]
36. Apicidin sensitizes pancreatic cancer cells to gemcitabine by epigenetically regulating MUC4 expression.
Ansari D; Urey C; Hilmersson KS; Bauden MP; Ek F; Olsson R; Andersson R
Anticancer Res; 2014 Oct; 34(10):5269-76. PubMed ID: 25275019
[TBL] [Abstract][Full Text] [Related]
37. STAT1-mediated inhibition of FOXM1 enhances gemcitabine sensitivity in pancreatic cancer.
Liu C; Shi J; Li Q; Li Z; Lou C; Zhao Q; Zhu Y; Zhan F; Lian J; Wang B; Guan X; Fang L; Li Z; Wang Y; Zhou B; Yao Y; Zhang Y
Clin Sci (Lond); 2019 Mar; 133(5):645-663. PubMed ID: 30782607
[TBL] [Abstract][Full Text] [Related]
38. CUDC-101 enhances the chemosensitivity of gemcitabine-treated lymphoma cells.
Li H; Cui R; Ji M; Jin SY
Leuk Res; 2021 Jul; 106():106575. PubMed ID: 33878513
[TBL] [Abstract][Full Text] [Related]
39. The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer.
Hashim YM; Vangveravong S; Sankpal NV; Binder PS; Liu J; Goedegebuure SP; Mach RH; Spitzer D; Hawkins WG
J Exp Clin Cancer Res; 2017 Jan; 36(1):14. PubMed ID: 28095907
[TBL] [Abstract][Full Text] [Related]
40. [Role of nuclear factor-kappaB on emodin-induced sensitization of pancreatic cancer to gemcitabine].
Liu A; Hu YS; Wang ZH; Tang LL; Ke PY; Lin SZ
Yao Xue Xue Bao; 2011 Feb; 46(2):146-52. PubMed ID: 21542284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
